1.6 million people are killed worldwide each year due to ovarian, endometrial, bladder and prostate cancers. The key to making treatment breakthrough is early diagnosis.PROTBIOFLUID is a new network for developing innovative early diagnostic techniques and for spreading this knowledge through the medical community by a systematic exchange of staff to create high impact benefits to patients and transform the way these cancers are managed.Our overall science objective is to study biofluids in cancer patients in order to determine specific proteomic profiles to lay the foundation for the development of a simple to use diagnostic tool that will become ubiquitous in the medium-to-long-term. Our objectives to create this impact are:1. Establish new methods for proteomic identification of biomarkers in biofluids for the early diagnosis and prognosis of cancer2. Evaluate molecular markers and therapeutic targets of metastasis through the use of preclinical animal modelsCurrently the know-how to reach these objectives exists but the field is highly fragmented. Therefore, we need this IRSES project as a catalyst for a focused network to create the critical mass to solve very pressing treatment problems. We have selected leading research partners with established relations of trust and reciprocity and who bring the correct combinations of complementary expertise. To effect the interlinking of research lines we have designed a systematic exchange of both very senior staff and those at earlier phases of their career. Through this mechanism we will achieve both high level knowledge exchanges as well as knowledge transfer through teaching and ‘hands on’ experience of best practice.At the end of the PROTBIOFLUID we will have agreed a framework for joint programming between partner institutions. This first nucleus of teams will be the core of a growing network of excellence that will transform both what and how things are done in the treatment of these deadly cancers